Literature DB >> 22745174

Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120.

Anthony P West1, Ron Diskin, Michel C Nussenzweig, Pamela J Bjorkman.   

Abstract

A large number of anti-HIV-1 antibodies targeting the CD4-binding site (CD4bs) on the envelope glycoprotein gp120 have recently been reported. These antibodies, typified by VRC01, are remarkable for both their breadth and their potency. Crystal structures have revealed a common mode of binding for several of these antibodies; however, the precise relationship among CD4bs antibodies remains to be defined. Here we analyze existing structural and sequence data, propose a set of signature features for potent VRC01-like (PVL) antibodies, and verify the importance of these features by mutagenesis. The signature features explain why PVL antibodies derive from a single germ-line human V(H) gene segment and why certain gp120 sequences are associated with antibody resistance. Our results bear on vaccine development and structure-based design to improve the potency and breadth of anti-CD4bs antibodies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22745174      PMCID: PMC3409792          DOI: 10.1073/pnas.1208984109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site.

Authors:  Yu Feng; Krisha McKee; Karen Tran; Sijy O'Dell; Stephen D Schmidt; Adhuna Phogat; Mattias N Forsell; Gunilla B Karlsson Hedestam; John R Mascola; Richard T Wyatt
Journal:  J Biol Chem       Date:  2011-12-13       Impact factor: 5.157

2.  Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing.

Authors:  Xueling Wu; Tongqing Zhou; Jiang Zhu; Baoshan Zhang; Ivelin Georgiev; Charlene Wang; Xuejun Chen; Nancy S Longo; Mark Louder; Krisha McKee; Sijy O'Dell; Stephen Perfetto; Stephen D Schmidt; Wei Shi; Lan Wu; Yongping Yang; Zhi-Yong Yang; Zhongjia Yang; Zhenhai Zhang; Mattia Bonsignori; John A Crump; Saidi H Kapiga; Noel E Sam; Barton F Haynes; Melissa Simek; Dennis R Burton; Wayne C Koff; Nicole A Doria-Rose; Mark Connors; James C Mullikin; Gary J Nabel; Mario Roederer; Lawrence Shapiro; Peter D Kwong; John R Mascola
Journal:  Science       Date:  2011-08-11       Impact factor: 47.728

3.  Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding.

Authors:  Johannes F Scheid; Hugo Mouquet; Beatrix Ueberheide; Ron Diskin; Florian Klein; Thiago Y K Oliveira; John Pietzsch; David Fenyo; Alexander Abadir; Klara Velinzon; Arlene Hurley; Sunnie Myung; Farid Boulad; Pascal Poignard; Dennis R Burton; Florencia Pereyra; David D Ho; Bruce D Walker; Michael S Seaman; Pamela J Bjorkman; Brian T Chait; Michel C Nussenzweig
Journal:  Science       Date:  2011-07-14       Impact factor: 47.728

4.  Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.

Authors:  Xueling Wu; Charlene Wang; Sijy O'Dell; Yuxing Li; Brandon F Keele; Zhongjia Yang; Hiromi Imamichi; Nicole Doria-Rose; James A Hoxie; Mark Connors; George M Shaw; Richard T Wyatt; John R Mascola
Journal:  J Virol       Date:  2012-03-14       Impact factor: 5.103

5.  The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection.

Authors:  Elin S Gray; Maphuti C Madiga; Tandile Hermanus; Penny L Moore; Constantinos Kurt Wibmer; Nancy L Tumba; Lise Werner; Koleka Mlisana; Sengeziwe Sibeko; Carolyn Williamson; Salim S Abdool Karim; Lynn Morris
Journal:  J Virol       Date:  2011-03-09       Impact factor: 5.103

6.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

7.  Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1.

Authors:  Aran F Labrijn; Pascal Poignard; Aarti Raja; Michael B Zwick; Karla Delgado; Michael Franti; James Binley; Veronique Vivona; Christoph Grundner; Chih-Chin Huang; Miro Venturi; Christos J Petropoulos; Terri Wrin; Dimiter S Dimitrov; James Robinson; Peter D Kwong; Richard T Wyatt; Joseph Sodroski; Dennis R Burton
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Increasing the potency and breadth of an HIV antibody by using structure-based rational design.

Authors:  Ron Diskin; Johannes F Scheid; Paola M Marcovecchio; Anthony P West; Florian Klein; Han Gao; Priyanthi N P Gnanapragasam; Alexander Abadir; Michael S Seaman; Michel C Nussenzweig; Pamela J Bjorkman
Journal:  Science       Date:  2011-10-27       Impact factor: 47.728

9.  High-resolution description of antibody heavy-chain repertoires in humans.

Authors:  Ramy Arnaout; William Lee; Patrick Cahill; Tracey Honan; Todd Sparrow; Michael Weiand; Chad Nusbaum; Klaus Rajewsky; Sergei B Koralov
Journal:  PLoS One       Date:  2011-08-04       Impact factor: 3.240

10.  Broad neutralization coverage of HIV by multiple highly potent antibodies.

Authors:  Laura M Walker; Michael Huber; Katie J Doores; Emilia Falkowska; Robert Pejchal; Jean-Philippe Julien; Sheng-Kai Wang; Alejandra Ramos; Po-Ying Chan-Hui; Matthew Moyle; Jennifer L Mitcham; Phillip W Hammond; Ole A Olsen; Pham Phung; Steven Fling; Chi-Huey Wong; Sanjay Phogat; Terri Wrin; Melissa D Simek; Wayne C Koff; Ian A Wilson; Dennis R Burton; Pascal Poignard
Journal:  Nature       Date:  2011-09-22       Impact factor: 49.962

View more
  139 in total

1.  Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth.

Authors:  Xuejun Chen; Tongqing Zhou; Stephen D Schmidt; Hongying Duan; Cheng Cheng; Gwo-Yu Chuang; Ying Gu; Mark K Louder; Bob C Lin; Chen-Hsiang Shen; Zizhang Sheng; Michelle X Zheng; Nicole A Doria-Rose; M Gordon Joyce; Lawrence Shapiro; Ming Tian; Frederick W Alt; Peter D Kwong; John R Mascola
Journal:  Immunity       Date:  2021-01-15       Impact factor: 31.745

2.  Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody.

Authors:  Shannon R Esswein; Harry B Gristick; Andrea Jurado; Avery Peace; Jennifer R Keeffe; Yu E Lee; Alisa V Voll; Mohsan Saeed; Michel C Nussenzweig; Charles M Rice; Davide F Robbiani; Margaret R MacDonald; Pamela J Bjorkman
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-22       Impact factor: 11.205

3.  Identification of Near-Pan-neutralizing Antibodies against HIV-1 by Deconvolution of Plasma Humoral Responses.

Authors:  Mohammad Mohseni Sajadi; Amir Dashti; Zahra Rikhtegaran Tehrani; William D Tolbert; Michael S Seaman; Xin Ouyang; Neelakshi Gohain; Marzena Pazgier; Dongkyoon Kim; Guy Cavet; Jean Yared; Robert R Redfield; George K Lewis; Anthony L DeVico
Journal:  Cell       Date:  2018-05-03       Impact factor: 41.582

4.  Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies.

Authors:  Allan deCamp; Peter Hraber; Robert T Bailer; Michael S Seaman; Christina Ochsenbauer; John Kappes; Raphael Gottardo; Paul Edlefsen; Steve Self; Haili Tang; Kelli Greene; Hongmei Gao; Xiaoju Daniell; Marcella Sarzotti-Kelsoe; Miroslaw K Gorny; Susan Zolla-Pazner; Celia C LaBranche; John R Mascola; Bette T Korber; David C Montefiori
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

5.  Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues.

Authors:  Anthony P West; Louise Scharf; Joshua Horwitz; Florian Klein; Michel C Nussenzweig; Pamela J Bjorkman
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-10       Impact factor: 11.205

Review 6.  Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning.

Authors:  Peter D Kwong; John R Mascola; Gary J Nabel
Journal:  Nat Rev Immunol       Date:  2013-09       Impact factor: 53.106

Review 7.  Strategies to guide the antibody affinity maturation process.

Authors:  Nicole A Doria-Rose; M Gordon Joyce
Journal:  Curr Opin Virol       Date:  2015-04-24       Impact factor: 7.090

8.  Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign.

Authors:  Karen Tran; Christian Poulsen; Javier Guenaga; Natalia de Val; Natalia de Val Alda; Richard Wilson; Christopher Sundling; Yuxing Li; Robyn L Stanfield; Ian A Wilson; Andrew B Ward; Gunilla B Karlsson Hedestam; Richard T Wyatt
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

9.  Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies.

Authors:  Hongying Duan; Xuejun Chen; Jeffrey C Boyington; Cheng Cheng; Yi Zhang; Alexander J Jafari; Tyler Stephens; Yaroslav Tsybovsky; Oleksandr Kalyuzhniy; Peng Zhao; Sergey Menis; Martha C Nason; Erica Normandin; Maryam Mukhamedova; Brandon J DeKosky; Lance Wells; William R Schief; Ming Tian; Frederick W Alt; Peter D Kwong; John R Mascola
Journal:  Immunity       Date:  2018-07-31       Impact factor: 31.745

10.  Rational HIV immunogen design to target specific germline B cell receptors.

Authors:  Joseph Jardine; Jean-Philippe Julien; Sergey Menis; Takayuki Ota; Oleksandr Kalyuzhniy; Andrew McGuire; Devin Sok; Po-Ssu Huang; Skye MacPherson; Meaghan Jones; Travis Nieusma; John Mathison; David Baker; Andrew B Ward; Dennis R Burton; Leonidas Stamatatos; David Nemazee; Ian A Wilson; William R Schief
Journal:  Science       Date:  2013-03-28       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.